RARECast

A podcast by RARECast - Thursdays

Thursdays

Categories:

516 Episodes

  1. A New Therapy Offers A Different Approach to Inhibiting the Complement System

    Published: 5/28/2021
  2. Bringing Aberrant Proteins Back into the Fold

    Published: 5/20/2021
  3. A Cat who Curates Rare Mice

    Published: 5/13/2021
  4. Putting the Patient at the Center of Rare Disease Clinical Trials

    Published: 5/6/2021
  5. Creating a Toolkit to Accelerate the Development of Gene Editing Therapies

    Published: 4/29/2021
  6. PTC Looks to Advanced Therapies

    Published: 4/22/2021
  7. Going to Extreme Lengths

    Published: 4/15/2021
  8. Everything’s up to Date in Kansas City, at Least When It Comes to Genomics

    Published: 4/8/2021
  9. Choosing the Right Viral Vector for a Gene Therapy

    Published: 4/1/2021
  10. A Software Platform to Give Patients the Tools to Build Treatments for Rare Genetic Diseases

    Published: 3/25/2021
  11. Side Effects: The Toll a Rare Disease Can Take on a Family in Pursuit of a Cure

    Published: 3/19/2021
  12. Realizing the Potential of CRISPR Gene Editing

    Published: 3/12/2021
  13. Understanding the Economic Toll of Rare Disease in the United States

    Published: 3/4/2021
  14. The Promise of Gene-Based Therapies for Neurodegenerative Conditions

    Published: 2/25/2021
  15. Moving Beyond Viral Vectors for Gene Therapies

    Published: 2/19/2021
  16. Acquisitions Help Jazz Build Toward Commercial Crescendo

    Published: 2/12/2021
  17. Powerful Gene Editing Approach Offers the Promise of Correcting a Range of Rare Diseases

    Published: 2/5/2021
  18. A Child's-Eye-View of Clinical Trials

    Published: 1/29/2021
  19. Using Nanoliposomes to Make Cancer Therapies Safer and More Effective

    Published: 1/21/2021
  20. Accelerating Treatments for Rare Disease through Data Sharing

    Published: 1/14/2021

10 / 26

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.